Drug Trial Radar · NCT05785767
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
149
Actual
Start
Jun 30, 2023
Primary completion
Sep 28, 2027
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life
Conditions
- Advanced Non-Small Cell Lung Cancer
Interventions
fianlimabDrug
Administered per the protocol
cemiplimabDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) as assessed by blinded independent central review (BICR), using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Time frame: Up to 136 weeks
Locations
106 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center
Tucson, Arizona
Yuma Regional Medical Center
Yuma, Arizona
Emad Ibrahim, MD, Inc.
Redlands, California
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut
Clermont Oncology Center
Clermont, Florida
Miami Veterans Administration HealthCare System
Miami, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
Pinellas Hematology and Oncology
St. Petersburg, Florida
Tallahassee Memorial Healthcare
Tallahassee, Florida
Moffitt Cancer Center
Tampa, Florida
University of Illinois
Chicago, Illinois
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
Hattiesburg Clinic
Hattiesburg, Mississippi
Mercy South
St Louis, Missouri
St. Vincent Healthcare
Billings, Montana
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
Clinical Research Alliance Inc
Westbury, New York
Gabrail Cancer Center Research
Canton, Ohio
University of Tennessee Medical Center
Knoxville, Tennessee
Renovatio Clinical
El Paso, Texas
MD Anderson Cancer Center
Houston, Texas
University of Virginia Medical Center
Charlottesville, Virginia
Bon Secours Cancer Institute Richmond
Midlothian, Virginia
Macquarie University Health Science Center (MQ Health)
Macquarie Park, New South Wales, Australia
Riverina Cancer Care Centre (RCCC)
Wagga Wagga, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Ballarat Regional Integrated Cancer Centre (BRICC)
Ballarat, Victoria, Australia
Bendigo Hospital
Bendigo, Victoria, Australia
British Columbia Cancer Center-Kelowna
Kelowna, British Columbia, Canada
Israeli Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Research Institute of Clinical Medicine
Tbilisi, Georgia
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, Georgia
NNLE New Vision University Hospital
Tbilisi, Georgia
The Institute of Clinical Oncology
Tbilisi, Georgia
TIM - Tbilisi Institute of Medicine
Tbilisi, Georgia
JSC Evex Hospitals - Caraps Medline
Tbilisi, Georgia
Cancer Center of Adjara
Batumi, Adjara, Georgia
Shaare Zedek Medical Center
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Assuta Medical Centers
Tel Aviv, Israel
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.